Astellas makes changes to management structure

Will dissolve the positions of QA and RA Head at Astellas Pharma

Japanese pharmaceutical firm Astellas has made changes to its management structure that aim to improve global product compliance and streamline global drug development.

From 1 April, all Heads of Global Development, Global Regulatory Affairs, Global Clinical Research Quality Assurance and Global Quality Assurance will report to the Chief Medical Officer. As a result, the positions of QA and RA Head of Astellas Pharma will cease to exist.

You may also like

Regulatory

Astellas' Vyloytm plus chemo gains FDA approval for gastric adenocarcinoma

The drug is the first CLDN18.2 targeted therapy to be approved in the US, and can further extend a patient's PFS and OS compared with chemotherapy alone
Regulatory

Padcev plus Keytruda approved for advanced urothelial cancer by the EC

The therapeutic combination will now be named as the first-line, standard of care treatment for metastatic or advanced bladder cancer
Research & Development

Astellas Pharma doses first patient in Phase III trial for Fezolinetant

Fezolinetant aims to mitigate the impact of hot flushes, which are the most common side effect associated with endocrine therapy for breast cancer
Manufacturing

Astellas begins construction of manufacturing site in Tralee

600 construction jobs and 100 specialised engineering, science and technology roles will be created from the project
Regulatory

Ubiquigent enters agreement with Astellas subsidiary, Nanna Therapeutics

Agreement leverages Ubiquigent’s DUB-focused drug discovery platform to support the development of novel therapeutic candidates for multiple disease targets selected by Nanna Therapeutics
Manufacturing

Astella invests $3.5m in antibody drug facility

Drug producer Astella is set to submit a planning application to build a new facility in Tralee (County Kerry), Ireland, to expand its capacity to develop antibody drugs
Ingredients

Therapeutic: zolbetuximab for gastric cancer

Stomach cancer is the fifth most commonly diagnosed form of cancer, with risk factors including age, smoking, H. pylori infection and gastro-oesophageal reflux disease
Subscribe now